|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 20, 2017 ) According to Publisher, the Global Orphan Drug market is estimated at $145.89 million in 2016 and is expected to reach $265.63 million by 2022 growing at a CAGR of 10.5% from 2016 to 2022. Rising focus of big pharmaceutical companies on orphan drug improvement, increasing occurrence of rare diseases, government incentives for orphan medicine are some factors favouring the market growth. However, some factors such as high initial investment that leads to higher per patient treatment cost, reimbursement uncertainties and high cost of drug development are hindering the market. North America registered significant growth for the market during the forecast period due to rising healthcare spending, constructive government initiatives, growing occurrence of chronic diseases and small timeline required for orphan drug development.
For more information about this report: http://www.reportsweb.com/orphan-drug-global-market-outlook-2016-2022
Some of the key players in the market include Abbott Laboratories, AbbVie Inc., Alexion Pharmaceuticals, Amgen, Inc., Bayer Healthcare, Boehringer Ingelheim GmbH, Bristol Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, Genentech, Janssen Biotech, Inc.,
Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer Inc., Roche Holding AG, Sanofi Aventis and Vertex Pharmaceuticals.
Drug Types Covered:
-Biological orphan drugs
-Non-biological orphan drugs
Applications Covered:
-Blood-related disorders
-Nephrology
-Neurology
-Oncology
-Infectious diseases
-Cystic fibrosis
-Other Applications
Technologies Covered:
-DNA recombination
-Hybridoma and gene mapping
-Transgenic
-Other Technologies
Pharmacological classes Covered:
-Enzyme replacement
-Gene and chromosome expression
-Protein replacement
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001716628/sample
Indications Covered:
-Acute Myeloid Leukemia
-Duchenne Muscular Dystrophy
-Glioma
-Graft vs Host Disease
-Multiple Myeloma
-Non-Hodgkin Lymphoma
-Ovarian Cancer
-Pancreatic Cancer
-Renal Cell Carcinoma
-Other Indications
Regions Covered:
-North America
-US
-Canada
-Mexico
-Europe
-Germany
-France
-Italy
-UK
-Spain
-Rest of Europe
-Asia Pacific
-Japan
-China
-India
-Australia
-New Zealand
-Rest of Asia Pacific
-Rest of the World
-Middle East
-Brazil
-Argentina
-South Africa
-Egypt
Company Profiling
12.1 Abbott Laboratories
12.2 AbbVie Inc.
12.3 Alexion Pharmaceuticals
12.4 Amgen, Inc.
12.5 Bayer Healthcare
12.6 Boehringer Ingelheim GmbH
12.7 Bristol Myers Squibb
12.8 Celgene Corporation
12.9 F. Hoffmann-La Roche AG
12.10 Genentech
12.11 Janssen Biotech, Inc.
12.12 Johnson & Johnson
12.13 Merck & Co., Inc.
12.14 Novartis
12.15 Pfizer Inc.
12.16 Roche Holding AG
12.17 Sanofi Aventis
12.18 Vertex Pharmaceuticals
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001716628/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
